nucleoside

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

... ritonavir, twice-daily, plusinvestigator-selected nucleoside reverse transcriptase inhibitors(NRTIs) and optional use of enfuvirtide. Results from the DUET-1 study showed that significantly morepatients (56 percent; n=170) in the TMC125 arm achieved a confirmedundetectable viral load (less than 50 copies/mL),...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

...ior treatment historyand included a combination of nucleoside reverse transcriptaseinhibitors (NRTIs) with or without non-nucleoside reversetranscriptase inhibitors (NNRTIs). TITAN 48-week study results In the per-protocol analysis of 554 patients, among patientsrandomized to the PREZISTA/r arm (n=286) vs. th...

Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop

...udine Clevudine is an oral, once-daily pyrimidine nucleoside analogthat is in development for the treatment of ...t Racivir Racivir is an oral, once-daily cytidine nucleoside analog thatis in development as an HIV therapy for use in combination withother approved HIV drugs. ...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

...lopicitabine Valopicitabine is an investigational nucleoside polymeraseinhibitor being evaluated in ongoing clinical trials for thetreatment of hepatitis C. The most common adverse events reportedin valopicitabine clinical trials to date include nausea, vomiting,fatigue, diarrhea, headache, flu-like symptoms a...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

... ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myel...oster # M8 Phase I study of sapacitabine, an oral nucleoside analogue, inpatients with advanced leukemias or myelodysplastic syndromes. General Poster Session: ...

ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses

...istant clinicalisolates and has shown synergy with nucleoside RTIs (NRTIs) inpreclinical studies. The resistance profile of ANX-201 is uniqueamong approved RTIs and contains mutations that have been shown toresensitize NRTI-resistant virus. In preclinical studies, ANX-201has shown broad-spectrum antiviral activ...

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting

...her classes of HCVantiviral compounds, including a nucleoside chain terminator, aprotease inhibitor and interfer...terferon or other likely therapeuticdrugs, such as nucleoside chain terminators or protease inhibitors,may be feasible." About Genelabs Technologies Genelabs Te...

LANI completes Phase I in Japan and to commence Phase I in UK

...bronchiolitis, licensed toMedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus(HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trialsunderway with its lead compound for human rhinovirus (HRV) infection in patients withcompromised respiration or immune systems. ...

Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting

...al cases, have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti- hepatitis B therapy, including TYZEKA. Hepatic function should be mon...

Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

...Bristol-Myers Squibb, BARACLUDE(R) (entecavir) isa nucleoside analogue indicated for the treatment of chronichepatitis B virus infection in adults with evidence of active viralreplication with either evidence of persistent elevations in serumaminotransferases (ALT or AST) or histologically active disease.BARACL...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

...107 (the active moietyof NM283, valopicitabine), a nucleoside polymerase inhibitor. Thesein vitro experiments suggest that the combination of boceprevir andeither one of these polymerase inhibitors achieves additiveantiviral activity and a complementary resistance profile; thecombination of two agents increases...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

...CYC682), a novel nucleoside analogTuesday, April 17 8 AM - 12 PM Synergisti...2007. About sapacitabine Sapacitabine is an oral nucleoside analog prodrug that actsthrough a novel mechanism. The compound interferes with DNAsynthesis by caus...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR

... Minisymposium nucleoside compounds Cancer that do not Epigenetics incorporate into DNA selectively induce Room 304 A-C ...

Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL

...udine Clevudine is an oral, once-daily pyrimidine nucleoside analogthat we are developing for the treatment of ...tis C. R7128 is a prodrug of PSI-6130, apyrimidine nucleoside analog inhibitor of HCV RNA polymerase. Thecurrent R7128 Phase I clinical trial is a multiple center...

Avexa Reports Positive Phase IIb Result

... trial for apricitabine (ATC).ATC is Avexa's novel nucleoside reverse transcriptase inhibitor(NRTI) being developed for the treatment of HIV infection inpatients with drug-resistant HIV. The Phase IIb trial compared the effectiveness of ATC inreducing the viral load of patients with drug-resistant HIV withthe e...